SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-187949
Filing Date
2021-06-10
Accepted
2021-06-10 17:27:03
Documents
12
Period of Report
2021-06-08
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d168316d8k.htm   iXBRL 8-K 33487
  Complete submission text file 0001193125-21-187949.txt   157081

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ngm-20210608.xsd EX-101.SCH 3090
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ngm-20210608_lab.xml EX-101.LAB 18122
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ngm-20210608_pre.xml EX-101.PRE 11419
5 EXTRACTED XBRL INSTANCE DOCUMENT d168316d8k_htm.xml XML 3419
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38853 | Film No.: 211009071
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences